Shanghai Xuerong Bio-Technology Co. Ltd. Class A

Shanghai Xuerong Bio-Technology Co. Ltd. Class A

SSZSE:300511
3.97
CNY
-0.04
(-1.00%)
0.07EPS
69.76P/E
3.12BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A carries a market capitalization of 3.12B, placing it among publicly traded companies globally. Its enterprise value stands at 4.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.12B
Enterprise Value4.12B

Share Statistics

As of September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A has 640.85M shares outstanding.

Shares Outstanding640.85M

Valuation Ratios

As of September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 69.76. The price-to-sales ratio is 1.32, and the price-to-book ratio stands at 1.98.

PE Ratio69.76
PS Ratio1.32
PB Ratio1.98
P/TBV Ratio2.43

Enterprise Valuation

As of September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A trades at an EV/EBITDA multiple of 85.60 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 85.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.12B versus a market cap of 3.12B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.74
EV / EBITDA85.60
EV / EBIT85.60

Financial Position

As of September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A maintains a current ratio of 0.36, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 82.96, indicating elevated leverage, while an interest coverage ratio of 1.12 demonstrates limited ability to service its debt obligations.

Current Ratio0.36
Quick Ratio0.08
Debt / Equity82.96
Debt / EBITDA25.46
Interest Coverage1.12

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A posted a return on equity (ROE) of 3.13, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.77 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.26, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.22, useful for judging operating efficiency across full business cycles. The company generates approximately 1.23M in revenue per employee across its workforce of 1,920.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.43 indicates how many times Shanghai Xuerong Bio-Technology Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)3.13
Return on Assets (ROA)1.26
Return on Invested Capital (ROIC)1.77
Return on Capital Employed (ROCE)3.22
Revenue Per Employee1.23M
Employee Count1,920.00
Inventory Turnover5.43

Taxes

CNY

Over the twelve months ended September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A recorded 245,278.87 in income tax expense. That works out to an effective tax rate of 0.53, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 45.85M, leaving 44.75M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax245,278.87
Effective Tax Rate0.53

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A's stock has declined approximately 46.06% over the past 52 weeks. The 50-day moving average sits at 4.70, while the 200-day moving average is 5.91.

52-Week Price Change-46.06%
50-Day Moving Average4.70
200-Day Moving Average5.91

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A generated 2.36B in revenue and converted that into 44.75M in net income, yielding earnings per share of 0.07. EBITDA reached 48.10M, while operating income came in at 226.45M.

Revenue2.36B
Gross Profit403.27M
Operating Income226.45M
Pretax Income45.85M
Net Income44.75M
EBITDA48.10M
EBIT48.10M
Earnings Per Share (EPS)0.07

Balance Sheet

CNY

As of September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A holds 128.39M in cash and equivalents against 1.22B in total debt, resulting in a net debt position of 993.96M. Total book value stands at 1.58B, with working capital of -1.07B providing operational flexibility.

Cash & Cash Equivalents128.39M
Total Debt1.22B
Net Debt993.96M
Equity (Book Value)1.58B
Book Value Per Share2.46
Working Capital-1.07B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-241.87M

Margins

Over the twelve months ended September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A posted a gross margin of 17.08, reflecting its pricing power and cost economics. The operating margin of 9.59 and net profit margin of 1.90 provide insight into operational efficiency.

Gross Margin17.08
Operating Margin9.59
Pretax Margin1.94
Profit Margin1.90
EBITDA Margin2.04

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A paid dividends of 0.03 per share. The dividend payout ratio of 41.45 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 7.08, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanghai Xuerong Bio-Technology Co. Ltd. Class A shareholders.

Dividend Per Share0.03
Payout Ratio41.45
Shareholder Yield7.08

Stock Splits

Shanghai Xuerong Bio-Technology Co. Ltd. Class A's most recent stock split took place on April 23, 2018 with a 10:19 split ratio.

Last Split Date4/23/2018
Split Ratio10:19

Scores

As of September 30, 2026, Shanghai Xuerong Bio-Technology Co. Ltd. Class A has an Altman Z-Score of 1.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.29